Reports by Industry
Reports by Company
- Company Analysis(173)
- Company Profile(60)
Global Duchenne Muscular Dystrophy Therapeutics Market By Drug (Translarna, Emflaza, EXONDYS 51), By Therapeutic Approach (Steroid Therapy, Exon Skipping, Mutation Suppression) Forecast to 2022
Format : 
Adobe Reader (PDF) Upto 24 hour delivery
Publish Date : May, 2017| No. of Pages : 100
Please make your selection :
Electronic Access - Single User License
US$ 2500.00
CD-ROM Mail Delivery
US$ 2700.00
Hard Copy Mail Delivery
US$ 2700.00
Electronic Access - Multi-User License
US$ 3500.00
1. Analyst View
2. Research Methodology
3. Duchenne Muscular Dystrophy (DMD): An Overview
4. Market Dynamics
4.1 Market Drivers
4.1.1 Growing Prevalence of Duchenne Muscular Dystrophy
4.1.2 Rising Acceptance of Duchenne Muscular Dystrophy Drugs in the Market
4.1.3 Increasing Funding Support & Grants
4.1.4 Increasing Awareness
4.1.5 Robust and Opportunistic Pipeline
4.2 Restraints
4.2.1 Pediatric Neuromuscular Disease
4.2.2 Lack of Disease History and Research Participants
4.2.3 Diagnosis and Management of Duchenne Muscular Dystrophy in Developing Countries
4.2.4 High Cost of Care
4.3 Opportunities
4.3.1 PPMO: Next Generation Antisense Platform
4.3.2 Growing Market Opportunity in Emerging Countries
4.3.3 High Unmet Need for an Effective Disease Modifying Therapy
4.3.4 Gene Therapy
4.3.5 Utrophin Modulation
4.3.6 Biomarkers for Duchenne Muscular Dystophy
5. Global Duchenne Muscular Dystrophy Therapeutics Market Outlook 2022
6. Approved Drugs
6.1 Emflaza (deflazacort)
6.2 EXONDYS 51 (eteplirsen)
6.3 Translarna (ataluren)
7. Market Segmentation by Therapeutic Approach
7.1 Mutation Suppression
7.2 Steroid Therapy
7.3 Exon Skipping Therapy
8. Market Segmentation by Geography
8.1 Europe
8.2 North America
8.3 Asia Pacific
9. Clinical Trial Assessment & Pipeline Analysis
9.1 Clinical Trials
9.1.1 By Geography
9.1.1 By Geography
9.1.2 By Clinical Trial Phase
9.1.3 By Key Players
9.2 Pipeline Analysis
10. Industry Trends and Developments
10.1 Administration of Corticosteroids
10.2 Collaboration amongst Industry Players and Non-Industry Participants
10.3 Exon-Skipping Technology Crowding the DMD Therapeutics Industry
10.4 Carrier Screening for Duchenne Muscular Dystrophy
11. Strategic Alliances
12. Competitive Landscape
13. Key Player Analysis
13.1 Marathon Pharmaceuticals, LLC
13.2 PTC Therapeutics, Inc.
13.3 Sarepta Therapeutics, Inc.
13.4 ITALFARMACO S.p.A.
13.5 Santhera Pharmaceuticals
13.6 Bristol-Myers Squibb
13.7 ReveraGen BioPharma, Inc.
13.8 Catabasis Pharmaceuticals, Inc.
13.9 FibroGen, Inc.
13.10 NS Pharma, Inc.
13.11 Pfizer
13.12 Summit Therapeutics plc
13.13 Taiho Pharmaceutical Co., Ltd. (Division of Otsuka Holdings Co. Ltd.)
14. Future Outlook
Not able to find data you are looking for? Ask our Research Analyst.
media citation
- testtest
19 Jan, 2024 - Yourstory.com News @ Foodtech startup Swiggy launches Health Hub in Chennai
23 Mar, 2021 - Yourstory.com News @ Zomato forays into dietary supplements, makes its own 'made in India' brand
16 Mar, 2021 - View more
get in touch
Copyright © 2018, RNCOS, 2002-2018
About Us
Terms & Policy
Contact